Market Overview
Global Antibody-drug Conjugates (ADCs) market size was valued at USD 2.83 billion in 2024 and is projected to grow from USD 3.06 billion in 2025 to USD 3.98 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.1% during the forecast period.
Antibody-drug conjugates represent a revolutionary class of biopharmaceutical drugs designed as targeted therapies for cancer treatment. These precision medicines combine monoclonal antibodies with potent cytotoxic drugs through specialized chemical linkers, enabling selective delivery of chemotherapy agents to cancer cells while minimizing damage to healthy tissues. The three key components include: the antibody (targeting mechanism), the cytotoxic payload (therapeutic agent), and the linker (stability control).
USD 2.83 billion in 2024
2032 USD 3.98 billion by 2032
of 5.1%
ADCetris and Kadcyla Dominate the Market Due to High Efficacy in Targeted Cancer Therapy
The market is segmented based on type into:
ADCetris (brentuximab vedotin)
Kadcyla (trastuzumab emtansine)
Enhertu (fam-trastuzumab deruxtecan)
Trodelvy (sacituzumab govitecan)
Others
By Application
Breast Cancer Segment Leads Due to
Approvals
The
Breast cancer
Lymphoma
Leukemia
Lung cancer
Others
https://www.24lifesciences.com
Our Key Players
Takeda Pharmaceutical Company Limited (Japan)
Roche Holding AG (Switzerland)
Seattle Genetics, Inc. (U.S.)
ImmunoGen, Inc. (U.S.)
Gilead Sciences, Inc. (U.S.)
AstraZeneca PLC (UK)
Pfizer Inc. (U.S.)
